viimane versioon :
19/11/2024
Infostab
ingredientide nimekiri
nimekiri
Sobivus otsing
Y-liini sobivuse tabel
Viited
uurimisrühmad
valistab
plakat
Sidemed
sponsorid
Autor
Kasutusjuhend
ajakiri
Dactinomycin
keemiline struktuur
Kaubanduslikud nimed erinevates maades
Preparaatide nimed on näitlikud ja abianete sisaldus võib erineda sõltuvalt riigist ja laborist
Cosmegen
Ameerika ühendriigid, Argentiina, Austraalia, Austria, Iraan, Itaalia, Kanada, Kreeka, Malaisia, Mehhiko, Norra, Prantsusmaa, Rootsi, Soome, Sveits, uus-Meremaa
Cosmegen Lyovac
Iirimaa, Rumeenia, Suurbritannia
Dacilon
India, Maroko, Tšiili
Dacmozen
India
Dactino
India
Dactinomicina
Ecuador, Kolumbia, Maroko, Tšiili
Dactinomycin
uus-Meremaa
Lyovac Cosmegen
Belgia, Holland, Luksemburg, Saksamaa
Viited : Dactinomycin
tüüp
avaldamine
3
ajaleht
Trissel LA, Martinez JF.
Compatibility of amifostine with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
84
ajaleht
Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499.
99
ajaleht
Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
169
ajaleht
Trissel LA, Martinez JF.
Physical compatibility of melphalan with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1993 ; 50: 2359-2363.
182
ajaleht
Trissel LA, Gilbert DL, Martinez JF.
Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 56-60.
244
ajaleht
Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913.
249
ajaleht
Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
307
ajaleht
Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799.
334
ajaleht
Trissel LA, Tramonte SM, Grilley BJ.
Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 988-992.
335
ajaleht
Trissel LA, Bready BB, Kwan JW, Santiago NM.
Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 402-406.
492
ajaleht
Trissel LA, Parks NPT, Santiago NM.
Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2186-2189.
729
ajaleht
Rusmin S, Welton S, DeLuca P, DeLuca PP.
Effect of inline filtration on the potency of drugs administered intravenously.
Am J Hosp Pharm 1977 ; 34: 1071-1074.
857
ajaleht
Kanke M, Eubanks JL, DeLuca PP.
Binding of selected drugs to a “treated” inline filter.
Am J Hosp Pharm 1983 ; 40: 1323-1328.
905
ajaleht
Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017.
1178
ajaleht
Benvenuto JA, Anderson RW, Kerkof K, Smith RG, Loo TL.
Stability and compatibility of antitumor agents in glass and plastic containers.
Am J Hosp Pharm 1981 ; 38: 1914-1918.
1322
ajaleht
Ennis CE, Merritt RJ, Neff DN.
In vitro study of inline filtration of medications commonly administered to pediatric cancer patients.
JPEN 1983 ; 7: 156-158.
1410
ajaleht
Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145.
1423
ajaleht
Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518.
4153
Labor
Dactinomycin (Cosmegen Lyovac®) - Summary of Product Characteristics
Orphan Europe (UF) Limited 2014
Mentions Légales